一支上海国资背景的基金,在7月份的两次大笔出手引起业内关注。一是康华生物。上海生物医药产业并购基金持股80.2%的万可欣生物,成立仅半个月,就在7月下旬斥资18.5亿元,收购了疫苗企业康华生物21.9%的股份。二是微创医疗。上海生物医药产业并购基金入股后后占股约7.3%,收购金额约13亿元。一周内连续两次出手,都是大比例入股,且标的都是市值百亿的上市公司,尤其是微创医疗,上海生物医药产业并购基金,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.